Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety of one treatment of S-Caine™ Peel (skin numbing cream) applied on healthy skin before a painful dermatologic procedure in adults. This study will also evaluate how well the S-Caine™ Peel eases the pain of the procedure.
| Condition | Intervention | Phase |
|---|---|---|
|
Pain |
Drug: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%) |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | An Open-Label Safety Study to Evaluate the Use of S-Caine™ Peel (Lidocaine 7% and Tetracaine 7% Cream) in Adult Patients Undergoing a Minor or Major Dermal Procedure |
- Number of participants with adverse events [ Time Frame: 20-30 minutes ] [ Designated as safety issue: Yes ]To evaluate the safety of a single administration of S-Caine Peel in providing dermal anesthesia over intact skin prior to a minor and major dermal procedure in adults
- Adequacy of Anesthesia [ Time Frame: 20-30 minutes ] [ Designated as safety issue: No ]To evaluate the adequacy of anesthesia provided for the minor and major dermal procedure. The adequacy of anesthesia was evaluated by asking patients whether the study drug provided adequate pain relief for the procedure (yes or no), and by asking the investigator whether the study drug provided adequate anesthesia for the procedure (yes or no).
| Enrollment: | 408 |
| Study Start Date: | May 2005 |
| Study Completion Date: | September 2005 |
| Primary Completion Date: | September 2005 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: S-Caine Peel |
Drug: S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)
S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
Other Name: Pliaglis
|
Detailed Description:
The practice of dermatology is seeing a rise in the number of surgical and laser procedures as technological advances have expanded the number of conditions amenable to these evolving therapies. Skin biopsies, shave excisions, deep excisions, electro-surgical procedures, intralesional injections, and laser surgery are frequently performed by dermatologists on a daily basis. Some pain accompanies almost all of these procedures, and a local anesthetic is commonly used. Traditionally, intracutaneous injection of lidocaine (with or without epinephrine) has been the anesthetic of choice. However, patients undergoing these procedures are often afraid of needles and syringes and the pain associated with injections. As a result, topical anesthetic agents have been explored and developed as painless alternatives to injected anesthesia.
S-Caine™ Peel (lidocaine 7% and tetracaine 7% cream) consists of a new eutectic formulation of lidocaine and tetracaine. S-Caine Peel is a topical local anesthetic cream that forms a pliable peel on the skin when exposed to air. S-Caine Peel is not occluded during application.
The purpose of this study is to gain additional safety information for S-Caine Peel when used in minor and major dermal procedures in adults.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patient is 18 years of age or older.
- Patient elects to undergo a minor or major dermal procedure.
- Patient is able to read and understand a written informed consent and has signed and dated a written informed consent.
Exclusion Criteria:
- Patient has known allergies, contraindications or sensitivities to lidocaine, tetracaine, or other local anesthetics of the amide or ester type or to any components of the test materials.
- Patient has known active atopic dermatitis at the designated treatment site.
- Patient has damaged, denuded or broken skin at the designated treatment site.
- Patient is pregnant or breastfeeding.
- Patient has participated in an investigational study or clinical trial of an unapproved drug within the previous 30 days.
- Patient has enrolled in any previous study involving S-Caine Peel.
Contacts and Locations| United States, Florida | |
| International Dermatology Research Inc. | |
| Miami, Florida, United States, 33144 | |
| United States, Michigan | |
| Midwest Cutaneous Research | |
| Clinton Township, Michigan, United States, 48038 | |
| United States, New York | |
| Laser and Skin Surgery Center of New York | |
| New York, New York, United States, 10016 | |
| United States, Tennessee | |
| Tennessee Clinical Research Center | |
| Nashville, Tennessee, United States, 37215 | |
| United States, Texas | |
| Texas Dermatology Research Institute | |
| Dallas, Texas, United States, 75230 | |
| Principal Investigator: | Alicia Barba, MD | International Dermatology Research |
More Information
Additional Information:
No publications provided
| Responsible Party: | ZARS Pharma Inc. |
| ClinicalTrials.gov Identifier: | NCT00107835 History of Changes |
| Other Study ID Numbers: | SCP-45-05 |
| Study First Received: | April 8, 2005 |
| Last Updated: | June 4, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by ZARS Pharma Inc.:
|
Pain |
Additional relevant MeSH terms:
|
Tetracaine Lidocaine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions |
Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses Anti-Arrhythmia Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on May 22, 2013